30 results found.

B-cell Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, Rec Clinical Trial using fludarabine phosphate; rituximab; total-body irradiation; allogeneic hematopoietic stem cell transplantation; peripheral blood stem cell transplantation; cyclosporine; mycophenolate mofetil; laboratory biomarker analysis; pharmacological study

Fred Hutchinson Cancer Research Center - Recruiting 18 years or older.
- Nonmyeloablative Conditioning With Pre- and Post-Transplant Rituximab Followed by Related or Unrelated Donor Hematopoietic Cell Transplantation for Patients With Advanced Chronic Lymphocytic Leukemia: A Multi-Center Trial.
fludarabine phosphate; rituximab; total-body irradiation; allogeneic hematopoietic stem cell transplantation; peripheral blood stem cell transplantation; cyclosporine; mycophenolate mofetil; laboratory biomarker analysis; pharmacological study

Chronic Lymphocytic Leukemia, or Small Lymphocytic Lymphoma Clinical Trial using IPI-145; Ofatumumab

Infinity Pharmaceuticals, Inc. - Recruiting 18 years or older.
- A Phase 3 Study of IPI-145 Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma (DUO).
IPI-145; Ofatumumab

Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Diffuse Large Clinical Trial using GS-9973

Gilead Sciences - Recruiting 18 years or older.
- A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS-9973 in Subjects With Relapsed or Refractory Hematologic Malignancies.
GS-9973

Lymphocytic Leukemia, Chronic, Lymphoma, B-Cell Clinical Trial using GDC-0853

Genentech - Recruiting 18 years or older.
- AN OPEN-LABEL, PHASE I, DOSE-ESCALATION STUDY EVALUATING THE SAFETY AND TOLERABILITY OF GDC-0853 IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN'S LYMPHOMA AND CHRONIC LYMPHOCYTIC LEUKEMIA.
GDC-0853

Lymphocytic Leukemia, Chronic Clinical Trial using GDC-0199 (ABT-199); Obinutuzumab

Genentech - Recruiting 18 years or older.
- A Phase Ib Multicenter Dose-Finding And Safety Study Of GDC-0199 And Obinutuzumab in Patients With Relapsed Or Refractory Or Previously Untreated Chronic Lymphocytic Leukemia.
GDC-0199 (ABT-199); Obinutuzumab

Lymphocytic Leukemia, Chronic Clinical Trial using GDC-0199 (ABT-199); rituximab [MabThera/Rituxan]; bendamustine

Genentech - Recruiting 18 years or older.
- A Phase Ib, Open-Label Study Evaluating the Safety and Pharmacokinetics of GDC-0199 (ABT-199) in Combination With Bendamustine/Rituximab (BR) in Patients With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia.
GDC-0199 (ABT-199); rituximab [MabThera/Rituxan]; bendamustine

Solid Tumor, Ovarian Cancer, Non-small Cell Lung Cancer, Chronic Clinical Trial

Cancer Centre of Monoclonal Therapy, LLC - Recruiting 18 years or older.
- Prognostic Potential of Cell Surface Markers and Pim Kinases in Patients With Selected Refractory or Relapsed Hematologic Malignancies or Solid Tumors.

B Cell Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, or W Clinical Trial using AVL-292

Celgene Corporation - Recruiting 18 years or older.
- Phase 1b, Escalating Dose Study of AVL-292, a Bruton's Tyrosine Kinase (Btk) Inhibitor, as Monotherapy in Subjects With Relapsed and/or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia.
AVL-292

Chronic Lymphocytic Leukemia Clinical Trial using obinutuzumab; chemotherapy

Hoffmann-La Roche - Recruiting 18 years or older.
- A Multicenter, Open-label, Single-arm, Phase IIIb, International Study Evaluating the Safety of Obinutuzumab Alone or in Combination With Chemotherapy in Patients With Previously Untreated or Relapsed/Refractory Chronic Lymphocytic Leukemia.
obinutuzumab; chemotherapy

Chronic Lymphocytic Leukemia Clinical Trial using GDC-0199; Rituximab [MabThera/Rituxan]; Bendamustine

Hoffmann-La Roche - Recruiting 18 years or older.
- A MULTICENTER, PHASE III, OPEN-LABEL, RANDOMIZED STUDY IN RELAPSED/REFRACTORY PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA TO EVALUATE THE BENEFIT OF GDC-0199 (ABT-199) PLUS RITUXIMAB COMPARED WITH BENDAMUSTINE PLUS RITUXIMAB.
GDC-0199; Rituximab [MabThera/Rituxan]; Bendamustine

Indolent Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, or Clinical Trial using Idelalisib; Rituximab; Bendamustine; Ofatumumab; Fludarabine; Everolimus; Bortezomib; Chlorambucil; Lenalidomide

Gilead Sciences - Recruiting 18 years or older.
- A Phase I Study to Investigate the Safety and Clinical Activity of Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 mAb in Subjects With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia.
Idelalisib; Rituximab; Bendamustine; Ofatumumab; Fludarabine; Everolimus; Bortezomib; Chlorambucil; Lenalidomide

B-cell Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocyt Clinical Trial using alemtuzumab; rituximab; PGG beta-glucan; flow cytometry; laboratory biomarker analysis; DNA analysis; fluorescence in situ hybridization; polymerase chain reaction; polymorphism analysis; mutation analysis

Mayo Clinic - Recruiting 18 years or older.
- Early Treatment of High Risk Chronic Lymphocytic Leukemia With Alemtuzumab, Rituximab, and PGG Beta-Glucan: A Phase I/II Trial.
alemtuzumab; rituximab; PGG beta-glucan; flow cytometry; laboratory biomarker analysis; DNA analysis; fluorescence in situ hybridization; polymerase chain reaction; polymorphism analysis; mutation analysis

Lymphocytic Leukemia, Chronic Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- Non Interventional Study Aimed to Describe the Management of Relapse or Refractory Chronic Lymphocytic Leukemia (CLL) Patients Retreated by MabThera.

B-cell Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, Rec Clinical Trial using ofatumumab; dinaciclib; laboratory biomarker analysis; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase 1b/2 Study of Dinaciclib (SCH 727965) and Ofatumumab in Relapsed and Refractory CLL/SLL/B-PLL.
ofatumumab; dinaciclib; laboratory biomarker analysis; pharmacological study

B-cell Chronic Lymphocytic Leukemia, Cutaneous B-cell Non-Hodgkin Clinical Trial using ipilimumab; rituximab; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase I Study of Ipilimumab in Combination With Rituximab in Patients With Relapsed/Refractory CD20+ B-Cell Lymphoma.
ipilimumab; rituximab; laboratory biomarker analysis

B-cell Chronic Lymphocytic Leukemia, Cutaneous B-cell Non-Hodgkin Clinical Trial using alisertib; romidepsin; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase 1 Trial of MLN8237 Plus Romidepsin for Relapsed/Refractory Aggressive B-Cell and T-Cell Lymphomas.
alisertib; romidepsin; laboratory biomarker analysis

Chronic Lymphocytic Leukemia, or Small Lymphocytic Lymphoma Clinical Trial using Ibrutinib; Bendamustine hydrochloride; Rituximab; Placebo

Janssen Research & Development, LLC - Recruiting 18 years or older.
- Randomized, Double-blind, Placebo-controlled Phase 3 Study of Ibrutinib, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Combination With Bendamustine and Rituximab (BR) in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
Ibrutinib; Bendamustine hydrochloride; Rituximab; Placebo

Indolent Non-Hodgkin Lymphoma, Mantle Cell Lymphoma, or Chronic L Clinical Trial using SAR245409

Sanofi - Recruiting 18 years or older.
- A Phase 1b, Multicenter, Open-Label, Dose Escalation Study of SAR245409 to Evaluate the Safety, Tolerability and Clinical Activity of SAR245409 in Combination With Rituximab or Bendamustine Plus Rituximab in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia.
SAR245409

Leukemia Clinical Trial using therapeutic autologous lymphocytes; cyclophosphamide

Memorial Sloan-Kettering Cancer Center - Recruiting 18 years or older.
- A Phase I/IIa Trial For The Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19.
therapeutic autologous lymphocytes; cyclophosphamide

Leukemia, or Lymphoma Clinical Trial using valproic acid; western blotting; laboratory biomarker analysis; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Epigenetic Therapy With Valproic Acid, an HDAC Inhibitor, in Refractory/Relapsed Non-Hodgkin Lymphoma, Hodgkin's Disease and CLL.
valproic acid; western blotting; laboratory biomarker analysis; pharmacological study

Contiguous Stage II Small Lymphocytic Lymphoma, Noncontiguous Sta Clinical Trial using MOR00208; lenalidomide; Correlative Studies

Ohio State University Comprehensive Cancer Center - Recruiting 18 years to 80 years.
- A Phase II Study of MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia(CLL)/Small Lymphocytic Lymphoma (SLL)Prolymphocytic Leukemia (PLL) or Patients With Untreated CLL/SLL/PLL.
MOR00208; lenalidomide; Correlative Studies

Chronic Lymphocytic Leukemia, 17 p Deletion, or Cancer of the Blo Clinical Trial using ABT-199

AbbVie - Recruiting 18 years or older.
- A Phase 2 Open-Label Study of the Efficacy of ABT-199 (GDC-0199) in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia Harboring the 17p Deletion.
ABT-199

Chronic Lymphocytic Leukemia (CLL), or Small Lymphocytic Lymphoma Clinical Trial using Bendamustine and Rituximab Induction followed by Rituximab and Lenalidomide Maintenance

University of Wisconsin, Madison - Recruiting 18 years or older.
- HO11415: Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy Followed by Maintenance Rituximab (Rituxanr) and Lenalidomide (Revlimidr) in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL).
Bendamustine and Rituximab Induction followed by Rituximab and Lenalidomide Maintenance

Leukemia Lymphocytic Chronic B-Cell Clinical Trial using CC-292; Lenalidomide

Celgene Corporation - Recruiting 18 years or older.
- A Multicenter, Phase 1B, Open-Label Study to Determine the Safety and Activity of CC-292 in Combination With Lenalidomide in Subjects With Relapsed and /or Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma.
CC-292; Lenalidomide

Leukemia Clinical Trial using rituximab; cyclophosphamide; doxorubicin hydrochloride; prednisone; vincristine sulfate

National Cancer Institute (NCI) - Recruiting 18 years or older.
- CHOP Plus Rituximab (CHOP-R) in Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL) or CLL With Autoimmune Haemolytic Anemia (AIHA) or Richter's Transformation (RT).
rituximab; cyclophosphamide; doxorubicin hydrochloride; prednisone; vincristine sulfate

B-cell Chronic Lymphocytic Leukemia, Hematopoietic/Lymphoid Cance Clinical Trial using carfilzomib; Cytokine Assessment; Pharmacodynamic Studies; Proteosome Inhibition Assessment; Pharmacogenomic Studies

Ohio State University Comprehensive Cancer Center - Recruiting 18 years or older.
- A Phase I Study of Carfilzomib in Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)/Prolymphocytic Leukemia (PLL).
carfilzomib; Cytokine Assessment; Pharmacodynamic Studies; Proteosome Inhibition Assessment; Pharmacogenomic Studies

Chronic Lymphocytic Leukemia Clinical Trial using ofatumumab plus dexamethasone

Brno University Hospital - Recruiting 18 years or older.
- Ofatumumab Added to Dexamethasone in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia.
ofatumumab plus dexamethasone

Chronic Lymphocytic Leukemia Clinical Trial using Valproic acid

All India Institute of Medical Sciences, New Delhi - Recruiting 18 years or older.
- Use of Valproic Acid in Relapsed or Refractory Chronic Lymphocytic Leukemia.
Valproic acid

Leukemia Clinical Trial using Immunotoxin therapy; CAT-8015 immunotoxin; Biological therapy

Cambridge Antibody Technology - Recruiting 18 years or older.
- A Phase 1, Multicenter, Dose Escalation Study of CAT-8015 in Patients With Relapse or Refractory Chronic Lymphocytic Leukemia (CLL), Prolymphocytic Leukemia (PLL), or Small Lymphocytic Lymphoma (SLL).
Immunotoxin therapy; CAT-8015 immunotoxin; Biological therapy